Abstract: A crystal form and salt form of a bromine domain protein inhibitor represented by formula (I), a preparation method therefor, and a use of the crystal form and salt form in the preparation of a drug for treating diseases mediated by BET protein.

Abstract: A ground simulation device and method for an on-orbit manipulation of a space manipulator is provided. The ground simulation device includes: a dual-arm robot, configured to simulate the space manipulator operating a target object; a suspension device, including a fixed post and passive rods, where the passive rods are movably connected with a top end of the fixed post, and the target object is suspended to the passive rods; and a simulation platform, configured to fix the dual-arm robot and the suspension device thereon. The ground simulation device provides the passive rods on the suspension device and suspends the target object to the passive rods, thus overcoming the gravity of the target object. In addition, the passive rods can drive the target object to move under an influence of an external force, achieving a similar suspension effect to that in space, and providing a desired, safe, and reliable implementation effect.

Abstract: A modified nucleoside or nucleotide, the 3?-OH of the modified nucleoside or nucleotide being reversibly blocked; meanwhile, the present invention also relates to a kit comprising the nucleoside or nucleotide, and a sequencing method based on the nucleoside or nucleotide.

Abstract: Disclosed are a pixel driving circuit and method, and a display device. The pixel driving circuit includes: the first port of the operation module is electrically connected via the first switch unit to the compensation wire connected to the pixel driving module, the second port of the operation module is electrically connected to the compensation wire through the second switch unit; the first switch unit is configured to transmit the driving data provided by the pixel driving module to the operation module in the self-discharge phase, and the operation module is configured to perform the calculation on the driving data in the self-discharge phase to obtain compensation data; the second switch unit is configured to write the compensation data into the pixel driving module through the compensation wire in the data writing stage.

Abstract: This application belongs to the field of pharmaceutical technology, and relates to the crystals of glycyrrhizic acid derivatives, their crystalline and pharmaceutical compositions, and medical use thereof, and, in particular, to the crystalline form A, crystalline form B, crystalline form C, crystalline form D, and crystalline form E of magnesium isoglycyrrhizinate, the method of preparing the crystals, the crystalline and pharmaceutical compositions containing the crystals, and medical use thereof. The crystalline forms prepared according to this application have overcome the defects of the compound of Formula I prepared according to the prior art, such as solid caking, difficult filtration, hard drying, and poor clarity. They are also suitable for industrial production, and capable of improving product safety.

Abstract: The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)—N—((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2?. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.

Abstract: The present disclosure provides a display panel. The display panel includes a short circuit protection circuit, a pixel driving circuit, and an organic light-emitting element. The short circuit protection circuit includes a detection circuit electrically connected to the organic light-emitting element, and a control circuit electrically connected to the detection circuit and the pixel driving circuit. The detection circuit is configured to detect whether the organic light-emitting element is short-circuited. The control circuit is configured to control, in response to a detection result of the detection circuit, whether the pixel driving circuit performs driving. In the present disclosure, the display panel includes a plurality of pixel units arranged in rows and columns. This prevents the pixel driving circuit from burning the organic light-emitting element that is short-circuited or other adjacent organic light-emitting element.

Abstract: This application belongs to the field of pharmaceutical technology, and relates to the crystals of glycyrrhizic acid derivatives, their crystalline and pharmaceutical compositions, and medical use thereof, and, in particular, to the crystalline form A, crystalline form B, crystalline form C, crystalline form D, and crystalline form E of magnesium isoglycyrrhizinate, the method of preparing the crystals, the crystalline and pharmaceutical compositions containing the crystals, and medical use thereof. The crystalline forms prepared according to this application have overcome the defects of the compound of Formula I prepared according to the prior art, such as solid caking, difficult filtration, hard drying, and poor clarity. They are also suitable for industrial production, and capable of improving product safety.

Abstract: A pixel driving circuit includes a driving transistor connected in series between a first power supply voltage terminal and a second power supply voltage terminal. The driving transistor has a control terminal electrically connected to a first node, a first terminal electrically connected to a second node, and a second terminal electrically connected to a third node. The second node is located between the first power supply voltage terminal and the driving transistor. The third node is located between the second power supply voltage terminal and the driving transistor. A light-emitting element is connected in series between the third node and the second power supply voltage terminal. A voltage maintaining module is configured to maintain a voltage of the third node unchanged.

Abstract: The present disclosure provides a display panel. The display panel includes a short circuit protection circuit, a pixel driving circuit, and an organic light-emitting element. The short circuit protection circuit includes a detection circuit electrically connected to the organic light-emitting element, and a control circuit electrically connected to the detection circuit and the pixel driving circuit. The detection circuit is configured to detect whether the organic light-emitting element is short-circuited. The control circuit is configured to control, in response to a detection result of the detection circuit, whether the pixel driving circuit performs driving. In the present disclosure, the display panel includes a plurality of pixel units arranged in rows and columns. This prevents the pixel driving circuit from burning the organic light-emitting element that is short-circuited or other adjacent organic light-emitting element.

Abstract: Provided is a pixel driving circuit, including: a driving circuit configured to drive a light-emitting device to emit light; a first data writing circuit configured to write, under control of a control signal inputted to its control terminal, an initial voltage into a control terminal of the driving circuit; a second data writing circuit configured to store, under control of a control signal inputted to its control terminal, a voltage difference between an initial grayscale voltage and the initial voltage, and to couple, under control of the control signal, a display grayscale voltage with the voltage difference, so that a voltage of the control terminal of the driving circuit is coupled to a superposition of the display grayscale voltage and the voltage difference; and a storage circuit configured to store a driving voltage of the driving circuit.

Abstract: A pixel driving circuit includes a driving transistor connected in series between a first power supply voltage terminal and a second power supply voltage terminal. The driving transistor has a control terminal electrically connected to a first node, a first terminal electrically connected to a second node, and a second terminal electrically connected to a third node. The second node is located between the first power supply voltage terminal and the driving transistor. The third node is located between the second power supply voltage terminal and the driving transistor. A light-emitting element is connected in series between the third node and the second power supply voltage terminal. A voltage maintaining module is configured to maintain a voltage of the third node unchanged.

Abstract: A pixel driving circuit is provided, including: a driving transistor connected between a first power supply terminal and a second power supply terminal; a light-emitting device connected between a third node and a second power supply terminal; a first capacitor having a first terminal connected to a first node and a second terminal connected to a fourth node; a second capacitor having a first terminal connected to the first node; a first switch unit having a first terminal connected to a data signal terminal and a second terminal connected to the fourth node; a second switch unit having a first terminal connected to the second fixed potential terminal and a second terminal connected to the fourth node; and a third switch unit having a first terminal connected to the data signal terminal and a second terminal connected to the first node.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)-N-((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2?. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present invention relates to a method for preparing magnesium lithospermate B. The method is characterized in that: magnesium lithospermate B is extracted or purified from a Salvia miltiorrhiza plant material or a Salvia miltiorrhiza extract in the presence of an added magnesium salt. The present invention also relates to a high-purity magnesium lithospermate B product prepared by the method of the present invention, wherein the content of magnesium lithospermate B is more than 95% by weight.

Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.

Abstract: The present invention relates to a method for preparing magnesium lithospermate B. The method is characterized in that: magnesium lithospermate B is extracted or purified from a Salvia miltiorrhiza plant material or a Salvia miltiorrhiza extract in the presence of an added magnesium salt. The present invention also relates to a high-purity magnesium lithospermate B product prepared by the method of the present invention, wherein the content of magnesium lithospermate B is more than 95% by weight.